PTGX — Protagonist Therapeutics, Inc.

Protagonist Therapeutics Q4 2020 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Protagonist reported license and collaboration revenue of $28.6 million for the full year 2020, a significant increase from $0.2 million in 2019. The fourth quarter revenue was $5.7 million, up from $2.7 million in Q4 2019.
• The revenue growth was attributed to the recognition of revenue from collaboration activities with Janssen Biotech related to new assets.

2. Strategic Updates and Business Highlights

• Protagonist expanded its clinical pipeline to five new chemical entities (NCEs) across six clinical studies, with completion expected within the next two years.
• The company is focusing on three therapeutic areas:
  • Blood disorders (e.g., polycythemia vera and iron overload)
  • Inflammatory bowel disease (IBD)
  • Inflammatory and autoimmune diseases targeting the IL-23 pathway.
• Rusfertide (PTG-300), a key asset, showed promising results in a Phase 2 trial for polycythemia vera, demonstrating safety and effective hematocrit control, reducing the need for phlebotomy.

3. Forward Guidance and Outlook

• Protagonist expressed optimism about continuing momentum into 2021, with plans to present updates at various medical conferences throughout the year, not just at the end of the year.
• The company aims to clarify regulatory pathways with the FDA and EMA regarding their clinical studies, particularly for rusfertide.

4. Bad News, Challenges, or Points of Concern

• The company acknowledged uncertainties regarding the regulatory pathway for rusfertide, particularly in differentiating between low-risk and high-risk patients.
• There are ongoing discussions with the FDA, and clarity is expected in the first half of 2021, but the outcomes remain uncertain.
• The competitive landscape includes established therapies like Jakafi, which may pose challenges in market penetration.

5. Notable Q&A Insights

• Analysts inquired about the regulatory strategy for rusfertide, with Protagonist indicating that the primary endpoint would likely focus on maintaining hematocrit levels below 45%.
• There was discussion about the mechanism of action for their IBD candidate, PN-943, emphasizing the gut-restricted approach compared to systemic therapies.
• Protagonist is exploring additional indications for rusfertide beyond polycythemia vera, particularly in conditions requiring phlebotomy and those characterized by erythrocytosis.
• The collaboration with Janssen on IL-23 receptor antagonists is not limited to IBD, with potential applications in various diseases.

Overall, Protagonist Therapeutics demonstrated significant progress in its clinical pipeline and financial performance, while also navigating regulatory uncertainties and competitive pressures.